158 related articles for article (PubMed ID: 10160477)
1. Clinical and cost considerations in the pharmacotherapy of vulvovaginal candidiasis.
Fong IW
Pharmacoeconomics; 1996 Jun; 9(6):497-505. PubMed ID: 10160477
[TBL] [Abstract][Full Text] [Related]
2. Women's use of over-the-counter antifungal medications for gynecologic symptoms.
Ferris DG; Dekle C; Litaker MS
J Fam Pract; 1996 Jun; 42(6):595-600. PubMed ID: 8656170
[TBL] [Abstract][Full Text] [Related]
3. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes.
Yano J; Sobel JD; Nyirjesy P; Sobel R; Williams VL; Yu Q; Noverr MC; Fidel PL
BMC Womens Health; 2019 Mar; 19(1):48. PubMed ID: 30925872
[TBL] [Abstract][Full Text] [Related]
4. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol.
Lírio J; Giraldo PC; Amaral RL; Sarmento ACA; Costa APF; Gonçalves AK
BMJ Open; 2019 May; 9(5):e027489. PubMed ID: 31122991
[TBL] [Abstract][Full Text] [Related]
5. Survey of incidence, lifetime prevalence, and treatment of self-reported vulvovaginal candidiasis, United States, 2020.
Benedict K; Singleton AL; Jackson BR; Molinari NAM
BMC Womens Health; 2022 May; 22(1):147. PubMed ID: 35538480
[TBL] [Abstract][Full Text] [Related]
6. Chronic vaginal candidiasis. Management in the postmenopausal patient.
Nwokolo NC; Boag FC
Drugs Aging; 2000 May; 16(5):335-9. PubMed ID: 10917071
[TBL] [Abstract][Full Text] [Related]
7. Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s.
Mårdh PA; Wågström J; Landgren M; Holmén J
Infect Dis Obstet Gynecol; 2004 Jun; 12(2):99-108. PubMed ID: 15739824
[TBL] [Abstract][Full Text] [Related]
8. Treatment of recurrent vulvovaginal candidiasis.
Ringdahl EN
Am Fam Physician; 2000 Jun; 61(11):3306-12, 3317. PubMed ID: 10865926
[TBL] [Abstract][Full Text] [Related]
9. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service.
Shah V; Cyril A; Koleoso P; Ragutharan A; Faiz M; Pushpakanthan P
Br J Gen Pract; 2024 Jun; 74(suppl 1):. PubMed ID: 38902100
[TBL] [Abstract][Full Text] [Related]
11. The development of evidence-based guidelines for over-the-counter treatment of vulvovaginal candidiasis.
Bond CM; Watson MC;
Pharm World Sci; 2003 Aug; 25(4):177-81. PubMed ID: 12964498
[TBL] [Abstract][Full Text] [Related]
12. Physicians' perceptions of the impact of the reclassification of vaginal antifungal agents.
Taylor CA; Lipsky MS
J Fam Pract; 1994 Feb; 38(2):157-60. PubMed ID: 8308507
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis.
Watson C; Calabretto H
Aust N Z J Obstet Gynaecol; 2007 Aug; 47(4):262-72. PubMed ID: 17627679
[TBL] [Abstract][Full Text] [Related]
14. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
[TBL] [Abstract][Full Text] [Related]
15. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society.
Mendling W; Brasch J; ; ; ;
Mycoses; 2012 Jul; 55 Suppl 3():1-13. PubMed ID: 22519657
[TBL] [Abstract][Full Text] [Related]
16. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis.
Sekhavat L; Tabatabaii A; Tezerjani FZ
J Infect Public Health; 2011 Sep; 4(4):195-9. PubMed ID: 22000847
[TBL] [Abstract][Full Text] [Related]
17. Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits.
Lipsky MS; Waters T; Sharp LK
J Am Board Fam Pract; 2000; 13(3):178-82. PubMed ID: 10826865
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study.
Špaček J; Kestřánek J; Jílek P; Leško D; Plucnarová S; Buchta V
Mycoses; 2017 Apr; 60(4):260-265. PubMed ID: 28066940
[TBL] [Abstract][Full Text] [Related]
19. The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis.
Fong IW
Genitourin Med; 1994 Apr; 70(2):124-6. PubMed ID: 8206471
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for fluconazole in the treatment of vulvovaginal candidiasis?
Patel HS; Peters MD; Smith CL
Ann Pharmacother; 1992 Mar; 26(3):350-3. PubMed ID: 1554957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
